Multistep, effective drug distribution within solid tumors
Metrics: PDF 552 views | HTML 389 views | ?
Amotz Shemi1, Elina Zorde Khvalevsky1, Rachel Malka Gabai1, Abraham Domb2, Yechezkel Barenholz3
1Silenseed Ltd., Jerusalem, Israel
2Faculty of Medicine - School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel
3Membrane and Liposome Research Lab, Hebrew University Hadassah Medical School, Jerusalem, Israel
Amotz Shemi, e-mail: email@example.com
Keywords: drug delivery, RNAi, tumor microenvironment, KRAS, solid tumor
Received: June 02, 2015 Accepted: September 10, 2015 Published: September 22, 2015
The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a miniature drug source offers an alternative to both systemic delivery and intratumoral injection. Presented here is a model of drug distribution from such a source, in a multistep process. At delivery onset the drug mainly affects the closest surroundings. Such ‘priming’ enables drug penetration to successive cell layers. Tumor ‘void volume’ (volume not occupied by cells) increases, facilitating lymphatic perfusion. The drug is then transported by hydraulic convection downstream along interstitial fluid pressure (IFP) gradients, away from the tumor core. After a week tumor cell death occurs throughout the entire tumor and IFP gradients are flattened. Then, the drug is transported mainly by ‘mixing’, powered by physiological bulk body movements. Steady state is achieved and the drug covers the entire tumor over several months. Supporting measurements are provided from the LODER™ system, releasing siRNA against mutated KRAS over months in pancreatic cancer in-vivo models. LODER™ was also successfully employed in a recent Phase 1/2 clinical trial with pancreatic cancer patients.
Primary Contact _
Elina Zorde Khvalevsky
Rachel Malka Gabai
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.